MANZF yields 3544.84% · JNJ yields 2.13%● Live data
📍 MANZF pulled ahead of the other in Year 1
Combined, MANZF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MANZF + JNJ for your $10,000?
Manz AG engages in the manufacture and sale of high-tech equipment in Germany, the United States, Taiwan, rest of Europe, China, and internationally. The company operates in five segments: Solar, Electronics, Energy Storage, Contract Manufacturing, and Service. The Solar segment provides system solutions for thin-film solar modules and CIGS thin-film technology. The Electronics segment offers production, assembly, and handling systems for the manufacture of flat screen displays, touch sensors, printed circuit boards, chip carriers, smartphones, tablet computers, laptops, wearables, and other consumer electronics; and automated assembly solutions for the automotive industry. The Energy Storage segment offers production, assembly, and handling equipment for lithium-ion battery cells, modules, and systems, as well as for capacitors for the manufacture of consumer electronics, power electronics, and other components of electrical powertrain. The Contract Manufacturing segment provides contract manufacturing services for equipment manufacturing, parts production, and assembly works for range of industries. The Service segment offers after-sales services, such as repair and maintenance, or conversion and upgrade services for machines and assemblies. Manz AG also provides simulation and factory planning, process and prototype development, and customer training services. The company was formerly known as Manz Automation AG and changed its name to Manz AG in June 2011. Manz AG was founded in 1987 and is based in Reutlingen, Germany.
Full MANZF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.